申请人:Takeda Chemical Industries, Ltd.
公开号:US04845219A1
公开(公告)日:1989-07-04
A compound of the general formula [I]: ##STR1## wherein R.sub.1 represents a higher alkyl group or an N-(higher alkyl)carbamoyl group, R.sub.2 represents a lower alkyl group, an acyl group having at least three carbon atoms, an N-(lower alkyl)carbamoyl group, an N-(lower alkyl)thiocarbamoyl group or a benzyl group, R represents a primary, secondary or tertiary amino group or a quaternary ammonium group, x is 1 or 2, y is a number of 0, 1 or 2, and z is an integer of 2-10, or a pharmaceutically acceptable salt thereof. The novel substances have both anti-tumor activity and platelet activating factor-inhibiting property, and they are effective as an anti-tumor agent without circulatory trouble.
通用式[I]的化合物:##STR1## 其中R.sub.1代表较高烷基基团或N-(较高烷基)氨基甲酰基团,R.sub.2代表较低烷基基团,至少有三个碳原子的酰基团,N-(较低烷基)氨基甲酰基团,N-(较低烷基)硫代氨基甲酰基团或苄基团,R代表一级、二级或三级氨基团或季铵基团,x为1或2,y为0、1或2的数字,z为2-10的整数,或其药学上可接受的盐。这些新物质既具有抗肿瘤活性又具有抑制血小板活化因子的性质,它们作为抗肿瘤药物在不引起循环问题的情况下是有效的。